Acumen Pharmaceuticals (ABOS) Return on Capital Employed (2021 - 2026)
Acumen Pharmaceuticals recorded quarterly Return on Capital Employed of 115.77% in Q1 2026, up 4.16% quarter-over-quarter from 120.79% in Q4 2025, and down 5322.0% year-over-year from 2.22% in Q1 2025.
Acumen Pharmaceuticals' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 115.77% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5322.0% year-over-year to 115.77%; the TTM figure through Mar 2026 stood at 115.77% (down 5322.0% YoY), while the FY2025 annual figure was 82.06%, down 3589.0% from the prior year.
- Return on Capital Employed came in at 115.77% for Q1 2026 at Acumen Pharmaceuticals, up from 120.79% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.3% in Q1 2022 to a low of 120.79% in Q4 2025.
- A 5-year average of 46.99% and a median of 27.43% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 466 bps in 2024 and sank 7020 bps in 2025, its largest moves.
- Acumen Pharmaceuticals' Return on Capital Employed stood at 23.55% in 2022, then climbed by 9 bps to 21.43% in 2023, then tumbled by 136 bps to 50.59% in 2024, then plunged by 139 bps to 120.79% in 2025, then advanced by 4 bps to 115.77% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 115.77%, 120.79%, and 102.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -115.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115.77% |
| Dec 31, 2025 | -120.79% |
| Sep 30, 2025 | -102.31% |
| Jun 30, 2025 | -88.16% |
| Mar 31, 2025 | -62.55% |
| Dec 31, 2024 | -50.59% |
| Sep 30, 2024 | -36.01% |
| Jun 30, 2024 | -27.43% |
| Mar 31, 2024 | -22.14% |
| Dec 31, 2023 | -21.43% |
| Sep 30, 2023 | -25.20% |
| Jun 30, 2023 | -30.00% |
| Mar 31, 2023 | -26.80% |
| Dec 31, 2022 | -23.55% |
| Sep 30, 2022 | -19.62% |
| Jun 30, 2022 | -15.17% |
| Mar 31, 2022 | -11.30% |
| Dec 31, 2021 | -8.61% |